Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654639 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02654639 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 4 participants.
The verdict
NCT02654639, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
Interventions
- DRUG Bevacizumab
- DRUG TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02654639
The ClinicalTrials.gov registry entry for NCT02654639 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02654639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02654639 about?
NCT02654639 is a clinical study titled "Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer". Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
What is the current status of trial NCT02654639?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2016-02. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02654639?
The interventions under investigation include: Bevacizumab (DRUG), TAS-102 (DRUG).
Who is sponsoring clinical trial NCT02654639?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.